Abstract
Almost 10 years after the discovery of Orphanin FQ / Nociceptin (OFQ/N) a large number of synthetic small molecule agonists and antagonists have been developed and tested in various physiological assays. Together with the academic work on the physiological functions of OFQ/N, we now have compelling evidence that this neuropeptide system might represent a valuable target for the development of drugs treating a variety of psychiatric disorders. Most prominently, the anti-stress and anxiolytic effects of OFQ/N agonists have been investigated although clinical trials have not yet been launched. Other possible applications of OFQ/N agonists and antagonists include treatment of depression, anorexia and rewarding aspects of drug addiction. This paper will summarize current developments and highlight the scientific achievements that have been made to elucidate the functions of OFQ/N with respect to psychiatric disorders.
Keywords: Orphanin FQ, nociceptin, neuropeptide, anxiety, stress, depression, obesity, anorexia, drug abuse, reward
CNS & Neurological Disorders - Drug Targets
Title: The Orphanin FQ / Nociceptin Receptor as a Novel Drug Target in Psychiatric Disorders
Volume: 5 Issue: 2
Author(s): Rainer K. Reinscheid
Affiliation:
Keywords: Orphanin FQ, nociceptin, neuropeptide, anxiety, stress, depression, obesity, anorexia, drug abuse, reward
Abstract: Almost 10 years after the discovery of Orphanin FQ / Nociceptin (OFQ/N) a large number of synthetic small molecule agonists and antagonists have been developed and tested in various physiological assays. Together with the academic work on the physiological functions of OFQ/N, we now have compelling evidence that this neuropeptide system might represent a valuable target for the development of drugs treating a variety of psychiatric disorders. Most prominently, the anti-stress and anxiolytic effects of OFQ/N agonists have been investigated although clinical trials have not yet been launched. Other possible applications of OFQ/N agonists and antagonists include treatment of depression, anorexia and rewarding aspects of drug addiction. This paper will summarize current developments and highlight the scientific achievements that have been made to elucidate the functions of OFQ/N with respect to psychiatric disorders.
Export Options
About this article
Cite this article as:
Reinscheid K. Rainer, The Orphanin FQ / Nociceptin Receptor as a Novel Drug Target in Psychiatric Disorders, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359628
DOI https://dx.doi.org/10.2174/187152706776359628 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Nicotinic Acetylcholine Receptors as Drug Targets
Current Drug Targets - CNS & Neurological Disorders Meet Our Editorial Board Member
Current Psychiatry Reviews Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Current Topics in Medicinal Chemistry Alcoholisms Evolutionary and Cultural Origins
Current Drug Abuse Reviews Directed Functional Connectivity of Posterior Cingulate Cortex and Whole Brain in Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research Mechanisms for Radioprotection by Melatonin; Can it be Used as a Radiation Countermeasure?
Current Molecular Pharmacology Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry Commentary ( Two Hits with One Shot – A Possibility of Simultaneous Targeting Motor Neuron Loss and Depression in ALS by Upregulating ADAR2 )
CNS & Neurological Disorders - Drug Targets Potentiation of Antidepressant-Like Activity with Lithium: Mechanism Involved
Current Drug Targets Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
Current Pediatric Reviews Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Prognostic Value of White Blood Cell in Acute Ischemic Stroke Patients
Current Neurovascular Research Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Gap Junction Blockers: An Overview of their Effects on Induced Seizures in Animal Models
Current Neuropharmacology